Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(02): 311-315
DOI: 10.1055/s-0042-1758663
Case Report

Anti-F-Actin Antibody Positivity on Indirect Immunofluorescence Assay Following Chinese and Alternative Medicine Therapy: A Case Report

Mala Mahto 
1   Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Patna, Patna, Bihar, India
,
Neha Rai 
1   Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Patna, Patna, Bihar, India
,
Soma Dey
1   Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Patna, Patna, Bihar, India
,
Ramesh Kumar
2   Department of Gastroenterology, All India Institute of Medical Sciences (AIIMS) Patna, Patna, Bihar, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Immunofluorescence on human epithelial type 2 cells is the standard screening assay for the detection of antinuclear antibodies (ANA). Cytoplasmic speckled patterns are a common finding. However, the less commonly reported ones include the cytoplasmic fibrillar patterns on indirect immunofluorescence technique (IIFT). The cytoplasmic fibrillar patterns include the cytoplasmic linear (AC-15), cytoplasmic filamentous (AC-16), and cytoplasmic segmental (AC-17). We report a case of cytoplasmic linear (F-actin) detected through IIFT during ANA screening in a 77-year-old man and later reconfirmed on liver mosaic biochip through IIFT on vascular smooth muscle substrate (VSM-47) without features suggestive of anti-smooth muscle antibody involvement post-complementary and alternative medicine therapy initiation.

Keywords

anti-F-actin antibody - indirect immunofluorescence - drug-induced autoimmune liver disease - giloy


Publication History

Article published online:
05 December 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights 2013; 4 (02) 39-53
    CrossrefPubMedGoogle Scholar
  • 2 Berreta-Piccoli BT, Miegi-Vergani G, Vergani D. Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol 2022; 63 (02) 124-137
    CrossrefPubMedGoogle Scholar
  • 3 Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 1956; 271 (6957): 1323-1326
    PubMedGoogle Scholar
  • 4 Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol 2018; 9: 609
    CrossrefPubMedGoogle Scholar
  • 5 Cancado ELR, Abrantes-Lemos CP, Terrabuio DRB. The importance of autoantibody detection in autoimmune hepatitis. Front Immunol 2015; 6: 222
    PubMedGoogle Scholar
  • 6 Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010; 24 (04) 225-231
    CrossrefPubMedGoogle Scholar
  • 7 Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120 (01) 239-249
    CrossrefPubMedGoogle Scholar
  • 8 Saha S, Ghosh S. Tinospora cordifolia: one plant, many roles. Anc Sci Life 2012; 31 (04) 151-159
    CrossrefPubMedGoogle Scholar
  • 9 Karousatos CM, Lee JK, Braxton DR, Fong TL. Case series and review of Ayurvedic medication induced liver injury. BMC Complement Med Ther 2021; 21 (01) 91
    CrossrefPubMedGoogle Scholar
  • 10 Nagral A, Adhyaru K, Rudra OS, Gharat A, Bhandare S. Herbal immune booster induced liver injury in the COVID-19 pandemic – a case series. J Clin Exp Hepatol 2021; 11 (06) 732-738
    CrossrefPubMedGoogle Scholar
  • 11 Kadir FA, Othman F, Abdulla MA, Hussan F, Hassandarvish P. Effect of Tinospora crispa on thioacetamide-induced liver cirrhosis in rats. Indian J Pharmacol 2011; 43 (01) 64-68
    CrossrefPubMedGoogle Scholar
  • 12 Kulkarni AV, Hanchanale P, Prakash V. et al; Liver Research Club India. Tinospora Cordifolia (giloy)-induced liver injury during the COVID-19 pandemic-multicenter nationwide study from India. Hepatol Commun 2022; 6 (06) 1289-1300
    CrossrefPubMedGoogle Scholar